921602-77-9 Usage
Uses
Used in Pharmaceutical Industry:
3,3-Difluorocyclohexanamine hydrochloride is used as a key intermediate in the synthesis of medications for its ability to form essential organic compounds. Its properties allow for the creation of a wide range of pharmaceutical products.
Used in Agrochemical Industry:
In the agrochemical sector, 3,3-Difluorocyclohexanamine hydrochloride is utilized as a precursor in the production of agrochemicals, contributing to the development of effective solutions for agricultural applications.
Used in Research and Development:
3,3-Difluorocyclohexanamine hydrochloride is employed as a starting material in research and development for the synthesis of innovative compounds and materials, driving advancements in various scientific fields.
Check Digit Verification of cas no
The CAS Registry Mumber 921602-77-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,1,6,0 and 2 respectively; the second part has 2 digits, 7 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 921602-77:
(8*9)+(7*2)+(6*1)+(5*6)+(4*0)+(3*2)+(2*7)+(1*7)=149
149 % 10 = 9
So 921602-77-9 is a valid CAS Registry Number.
921602-77-9Relevant articles and documents
Synthesis of gem-difluorocyclopentane/hexane building blocks
Melnykov, Kostiantyn P.,Nosik, Pavel S.,Kurpil, Bohdan B.,Sibgatulin, Dmitriy A.,Volochnyuk, Dmitriy M.,Ryabukhin, Sergey V.,Grygorenko, Oleksandr O.
, p. 60 - 66 (2017/05/17)
An approach to the preparation of gem-difluorocyclopentane/hexane-derived carboxylic acids and amines is described. Whereas for 3,3-difluoro-substituted cycloalkanones, straightforward deoxofluorination of the corresponding ketoesters led to the target compounds, in the case of 2,2-difluoro isomers, the bypass or alternative routes were necessary.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column, (2015/03/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
-
Page/Page column 101, (2013/07/31)
Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.